| abstract |
A method of culturing embryonic stem cells, induced pluripotent stem cells and/or differentiated cells in a culture medium comprising activin is described. In one aspect, the present disclosure features a pluripotent human stem cell, wherein the stem cell (i) genome editing resulting in loss of function of a cytokine inducible SH2-comprising protein (CISH) and (ii) TGF beta signaling genome editing that results in loss of function of an agonist of the pathway, or genome editing that results in loss of function of the adenosine A2a receptor. |